Can genes predict liver damage from MS drug?

NCT ID NCT01118130

Completed Knowledge-focused Sponsor: University of British Columbia Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study enrolled 300 people with multiple sclerosis who were taking beta-interferon. Researchers compared the genes of those who developed liver injury to those who did not, aiming to find genetic markers that predict this side effect. No new drug or treatment was tested.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which MS patients are at risk for liver damage from beta-interferon, leading to safer prescribing.
What could go wrong: This is an observational study, not a treatment trial. It only looks for genetic links, so it won't directly change care. Results may not apply to all MS patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

Dalhousie MS Research Unit

Halifax, Nova Scotia, Canada
Hôpital Notre-Dame MS clinic

Montreal, Quebec, Canada
London Health Sciences Centre MS clinic

London, Ontario, Canada
MS Clinic UBC Hospital

Vancouver, British Columbia, V6T 2B5, Canada
Winnipeg Health Sciences Centre

Winnipeg, Manitoba, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.